<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK47457" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK47457/" /><meta name="ncbi_pagename" content="CEBPA-Associated Familial Acute Myeloid Leukemia (AML) - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>CEBPA-Associated Familial Acute Myeloid Leukemia (AML) - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="CEBPA-Associated Familial Acute Myeloid Leukemia (AML)" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/04/28" /><meta name="citation_author" content="Kiran Tawana" /><meta name="citation_author" content="Jude Fitzgibbon" /><meta name="citation_pmid" content="20963938" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK47457/" /><meta name="citation_keywords" content="CEBPA-Dependent Familial Acute Myeloid Leukemia" /><meta name="citation_keywords" content="CEBPA-Dependent Familial Acute Myeloid Leukemia" /><meta name="citation_keywords" content="CCAAT/enhancer-binding protein alpha" /><meta name="citation_keywords" content="CEBPA" /><meta name="citation_keywords" content="CEBPA-Associated Familial Acute Myeloid Leukemia (AML)" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="CEBPA-Associated Familial Acute Myeloid Leukemia (AML)" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Kiran Tawana" /><meta name="DC.Contributor" content="Jude Fitzgibbon" /><meta name="DC.Date" content="2016/04/28" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK47457/" /><meta name="description" content="CEBPA-associated familial acute myeloid leukemia (AML) is defined as AML in which a heterozygous germline CEBPA pathogenic variant is present in a family in which multiple individuals have AML. In contrast, sporadic CEBPA-associated AML is defined as AML in which a CEBPA pathogenic variant(s) is identified in leukemic cells but not in the non-leukemic cells. Too few individuals with CEBPA-associated familial AML have been reported to be certain about the natural history of the disease. In the majority of individuals, the age of onset of familial AML appears to be earlier than sporadic AML; disease onset has been reported in persons as young as age 1.8 years and older than age 45 years. The prognosis of CEBPA-associated familial AML appears to be favorable compared with sporadic CEBPA-associated AML. Individuals with CEBPA-associated familial AML who have been cured of their initial disease may be at greater risk of developing additional independent leukemic episodes in addition to the risk of relapse due to preexisting clones." /><meta name="og:title" content="CEBPA-Associated Familial Acute Myeloid Leukemia (AML)" /><meta name="og:type" content="book" /><meta name="og:description" content="CEBPA-associated familial acute myeloid leukemia (AML) is defined as AML in which a heterozygous germline CEBPA pathogenic variant is present in a family in which multiple individuals have AML. In contrast, sporadic CEBPA-associated AML is defined as AML in which a CEBPA pathogenic variant(s) is identified in leukemic cells but not in the non-leukemic cells. Too few individuals with CEBPA-associated familial AML have been reported to be certain about the natural history of the disease. In the majority of individuals, the age of onset of familial AML appears to be earlier than sporadic AML; disease onset has been reported in persons as young as age 1.8 years and older than age 45 years. The prognosis of CEBPA-associated familial AML appears to be favorable compared with sporadic CEBPA-associated AML. Individuals with CEBPA-associated familial AML who have been cured of their initial disease may be at greater risk of developing additional independent leukemic episodes in addition to the risk of relapse due to preexisting clones." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK47457/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/cebpa-aml/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK47457/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C0279E04060010000000006AB0243.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK47457_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK47457_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cdk13-dis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/charge/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK47457_"><span class="title" itemprop="name"><i>CEBPA-</i>Associated Familial Acute Myeloid Leukemia (AML)</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: <i>CEBPA</i>-Dependent Familial Acute Myeloid Leukemia</div><p class="contrib-group"><span itemprop="author">Kiran Tawana</span>, MBChB, FRCPath and <span itemprop="author">Jude Fitzgibbon</span>, BA, PhD.</p><a data-jig="ncbitoggler" href="#__NBK47457_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK47457_ai__"><div class="contrib half_rhythm"><span itemprop="author">Kiran Tawana</span>, MBChB, FRCPath<div class="affiliation small">Barts Cancer Institute<br />Queen Mary University of London<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.lumq@anawat.k" class="oemail">ku.ca.lumq@anawat.k</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Jude Fitzgibbon</span>, BA, PhD<div class="affiliation small">Barts Cancer Institute<br />Queen Mary University of London<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.lumq@nobbigztif.j" class="oemail">ku.ca.lumq@nobbigztif.j</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">October 21, 2010</span>; Last Update: <span itemprop="dateModified">April 28, 2016</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="cebpa-aml.Summary" itemprop="description"><h2 id="_cebpa-aml_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>CEBPA-</i>associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> acute myeloid leukemia (AML) is defined as AML in which a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is present in a family in which multiple individuals have AML. In contrast, <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> <i>CEBPA</i>-associated AML is defined as AML in which a <i>CEBPA</i> pathogenic variant(s) is identified in leukemic cells but not in the non-leukemic cells. Too few individuals with <i>CEBPA</i>-associated familial AML have been reported to be certain about the natural history of the disease. In the majority of individuals, the age of onset of familial AML appears to be earlier than sporadic AML; disease onset has been reported in persons as young as age 1.8 years and older than age 45 years. The prognosis of <i>CEBPA-</i>associated familial AML appears to be favorable compared with sporadic <i>CEBPA</i>-associated AML. Individuals with <i>CEBPA</i>-associated familial AML who have been cured of their initial disease may be at greater risk of developing additional independent leukemic episodes in addition to the risk of relapse due to preexisting clones.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML is established by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a specimen that contains only non-leukemic cells from an individual with AML, or by observing <a class="def" href="/books/n/gene/glossary/def-item/segregation/">segregation</a> of a shared germline <i>CEBPA</i> pathogenic variant across <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment usually includes cytarabine/anthracycline-based induction and cytarabine-based consolidation chemotherapy. Hematopoietic stem cell transplantation (HSCT) from a volunteer unrelated donor (VUD) or appropriately screened family member should be reserved for individuals failing to achieve remission following standard induction therapy or for disease recurrence. Whenever possible, persons with AML should be treated as part of a clinical trial protocol.</p><p><i>Prevention of secondary complications:</i> Similar to that for other types of AML (i.e., administration of blood products such as red blood cell and platelet transfusions as needed; treatment of infections with antibiotics; and use of prophylactic antibiotics and anti-fungal agents during periods of severe neutropenia).</p><p><i>Surveillance:</i> Similar to that for other forms of AML. Because of the increased risk of leukemia recurrence in persons with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML, lifelong surveillance may be warranted.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Predisposition to <i>CEBPA-</i>associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Most individuals diagnosed with <i>CEBPA</i>-associated familial AML have had an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent who shares the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Germline <i>CEBPA</i> pathogenic variants exhibit complete or near-complete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for the development of AML in families reported to date. Each child of an affected individual has a 50% chance of inheriting the germline pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the germline <i>CEBPA</i> pathogenic variant in the family is known.</p></div></div><div id="cebpa-aml.Diagnosis"><h2 id="_cebpa-aml_Diagnosis_">Diagnosis</h2><p>To date there are no universally accepted guidelines for the detection of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants associated with acute myeloid leukemia (AML), although a useful algorithm has been proposed by <a class="bk_pop" href="#cebpa-aml.REF.nickels.2013.254">Nickels et al [2013]</a>.</p><div id="cebpa-aml.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>CEBPA-</i>associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML <b>should be suspected</b> in individuals with the following clinical and supportive laboratory findings:</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Individuals with AML who also have a family history of AML</div></li><li class="half_rhythm"><div>Individuals who have developed AML at an early age (&#x0003c;50 years)</div></li></ul><p><b>Supportive laboratory findings</b></p><ul><li class="half_rhythm"><div>Young individuals with AML whose leukemic cells have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in both copies of <i>CEBPA</i></div></li><li class="half_rhythm"><div>Normal <a class="def" href="/books/n/gene/glossary/def-item/karyotype/">karyotype</a> in leukemic cells</div></li><li class="half_rhythm"><div>A preponderance of French-American-British (FAB) Cooperative Group AML Classification subtypes M1 or M2 as established by morphologic analysis of peripheral blood or bone marrow blasts</div></li><li class="half_rhythm"><div>Auer rods seen in blasts (i.e., abnormal, needle-shaped or round, light blue or pink-staining inclusions found in the cytoplasm of leukemic cells)</div></li><li class="half_rhythm"><div>Aberrant CD7 expression on blasts as demonstrated by flow cytometry</div></li></ul><p>Note: A provisional diagnostic category of "AML with mutated <i>CEBPA</i>" was proposed in the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [<a class="bk_pop" href="#cebpa-aml.REF.arber.2008">Arber et al 2008</a>]. This classification is primarily intended for <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> AML and does not distinguish <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> forms of disease or the presence of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one or both copies of <i>CEBPA</i>; only the latter have favorable prognostic significance in AML.</p><p>For this <i>GeneReview</i>, the following definitions are used:</p><p><b><i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML</b> is defined by the presence of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Germline variants may be inherited across multiple generations or develop <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> in parental germ cells, prior to their transmission. Once inherited, they are present in every cell of an individual as part of their unique genetic make-up. Germline <i>CEBPA</i> pathogenic variants typically coincide with a family history of AML and the diagnosis is established by either of the following:</p><ul><li class="half_rhythm"><div>Detection of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a specimen that contains only non-leukemic cells from an individual with AML</div></li><li class="half_rhythm"><div>Detection of a shared <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> (and possibly asymptomatic) members of an AML <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a></div></li></ul><p><b>Sporadic <i>CEBPA-</i>associated</b>
<b>AML</b> is defined as AML in which a somatic <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) is acquired in leukemic cells alone; these variants are absent in all of the individual's non-leukemic cells (see <a href="#cebpa-aml.Molecular_Genetics">Molecular Genetics</a>).</p></div><div id="cebpa-aml.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a confirmed <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (see <a class="figpopup" href="/books/NBK47457/table/cebpa-aml.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="figcebpaamlTmoleculargenetictestingus" rid-ob="figobcebpaamlTmoleculargenetictestingus">Table 1</a>). Because <i>CEBPA</i>-associated familial AML develops from cells that have a pathogenic (cancer-predisposing) variant in both copies of <i>CEBPA,</i> leukemic cells frequently demonstrate both a germline and a somatic <i>CEBPA</i> variant at AML diagnosis. The germline pathogenic variant is typically a frameshift located in the <i>CEBPA</i> region encoding the N-terminal C/EBP&#x003b1; protein, while the second <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a> acquired in leukemic cells is typically in the region encoding the C-terminal (see <a href="#cebpa-aml.Molecular_Genetics">Molecular Genetics</a>).</p><p>Note: In the literature, the terms <i>CEBPA</i>dm and <i>CEBPA</i>sm may be used. These terms refer to leukemic cells with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in both copies of <i>CEBPA</i> ("<i>d</i>ouble <i>m</i>utation") or in only one copy of <i>CEBPA</i> ("<i>s</i>ingle <i>m</i>utation"). These terms alone do not specify if the pathogenic variant is <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> or somatic (see <a href="#cebpa-aml.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</a>).</p><p>Molecular testing approaches include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>CEBPA</i> is performed in a non-leukemic specimen.</div><div class="half_rhythm">Note: (1) Testing for a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should not be performed on blood or bone marrow during active AML. Testing a non-involved specimen, such as cells obtained by buccal swab/saliva, skin biopsy or cultured dendritic cells, is imperative. (2) It should be noted that <i>CEBPA</i> pathogenic variants are found in the leukemic cells of approximately 9% of persons with AML, including 15%-18% of persons with normal-<a class="def" href="/books/n/gene/glossary/def-item/karyotype/">karyotype</a> AML [<a class="bk_pop" href="#cebpa-aml.REF.arber.2008">Arber et al 2008</a>, <a class="bk_pop" href="#cebpa-aml.REF.renneville.2008.915">Renneville et al 2008</a>]. However, few of these individuals have a germline <i>CEBPA</i> pathogenic variant. (3) Testing of blood or bone marrow during complete remission from AML may also be performed to detect germline variants. The percentage of residual leukemic cells in remission samples is negligible, ensuring that somatic variants are not falsely classified as germline variants.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>CEBPA</i> and other genes of interest (see <a href="#cebpa-aml.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="cebpa-aml.T.molecular_genetic_testing_us" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>CEBPA</i>-Associated Familial Acute Myeloid Leukemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47457/table/cebpa-aml.T.molecular_genetic_testing_us/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cebpa-aml.T.molecular_genetic_testing_us_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>CEBPA</i></td><td headers="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;(11/11 families)&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="cebpa-aml.TF.1.1"><p class="no_margin">See <a href="/books/NBK47457/#cebpa-aml.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="cebpa-aml.TF.1.2"><p class="no_margin">See <a href="#cebpa-aml.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="cebpa-aml.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="cebpa-aml.TF.1.4"><p class="no_margin">Sequencing of the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> does not detect putative partial or complete <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions or variants in promoter regions. However, no such <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> variants causing <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML with mutated <i>CEBPA</i> have been reported to date.</p></div></dd><dt>5. </dt><dd><div id="cebpa-aml.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#cebpa-aml.REF.smith.2004.2403">Smith et al [2004]</a>, <a class="bk_pop" href="#cebpa-aml.REF.sellick.2005.1276">Sellick et al [2005]</a>, <a class="bk_pop" href="#cebpa-aml.REF.pabst.2008.5088">Pabst et al [2008]</a>, <a class="bk_pop" href="#cebpa-aml.REF.renneville.2009.804">Renneville et al [2009]</a>, <a class="bk_pop" href="#cebpa-aml.REF.nanri.2010.237">Nanri et al [2010]</a>, <a class="bk_pop" href="#cebpa-aml.REF.stelljes.2011.1209">Stelljes et al [2011]</a>, <a class="bk_pop" href="#cebpa-aml.REF.taskesen.2011.2469">Taskesen et al [2011]</a>, <a class="bk_pop" href="#cebpa-aml.REF.xiao.2011.5257">Xiao et al [2011]</a>, <a class="bk_pop" href="#cebpa-aml.REF.debeljak.2013.e73">Debeljak et al [2013]</a>, <a class="bk_pop" href="#cebpa-aml.REF.tawana.2015.1214">Tawana et al [2015]</a></p></div></dd><dt>6. </dt><dd><div id="cebpa-aml.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="cebpa-aml.TF.1.7"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd></dl></div></div></div></div></div><div id="cebpa-aml.Clinical_Characteristics"><h2 id="_cebpa-aml_Clinical_Characteristics_">Clinical Characteristics</h2><div id="cebpa-aml.Clinical_Description"><h3>Clinical Description</h3><p>Germline <i>CEBPA</i> pathogenic variants were first associated with the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> transmission of acute myeloid leukemia (AML) in 2004 [<a class="bk_pop" href="#cebpa-aml.REF.smith.2004.2403">Smith et al 2004</a>]. Over the last decade, more than ten families have been reported, all manifesting a highly penetrant AML <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> as described above. Given the limited number of individuals described in the literature, it is possible that the true range of clinical phenotypes may vary [<a class="bk_pop" href="#cebpa-aml.REF.pabst.2009.5303">Pabst &#x00026; Mueller 2009</a>] and ongoing investigation of this syndrome is essential.</p><p>The age of onset of <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML is variable, but appears to be earlier than <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> AML. Disease onset has been reported in persons as young as 1.8 years [<a class="bk_pop" href="#cebpa-aml.REF.debeljak.2013.e73">Debeljak et al 2013</a>] and older than 45 years [<a class="bk_pop" href="#cebpa-aml.REF.pabst.2008.5088">Pabst et al 2008</a>]. By contrast, the median age at diagnosis of persons with sporadic AML is 65 years.</p><p>From an analysis of ten pedigrees with <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML, the disease follows a course similar to <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> AML with <i>CEBPA</i> pathogenic variants in both copies (<i>CEBPA</i>dm)<i>.</i> The prognosis of individuals with familial AML appears to be favorable, with ten-year overall survival (OS) reaching 67%, compared to 54% OS of younger adults with sporadic AML associated with two <i>CEBPA</i> pathogenic variants and 29% OS with sporadic AML associated with a single <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#cebpa-aml.REF.tawana.2015.1214">Tawana et al 2015</a>].</p><p>Individuals with <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML who have been cured of their initial disease may be at greater risk of developing recurrent, independent leukemic episodes that are characterized by a different somatic <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from that observed in the original tumor clone. This phenomenon contrasts with relapse in individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> AML, where <i>CEBPA</i> pathogenic variants are stable throughout the disease course [<a class="bk_pop" href="#cebpa-aml.REF.tiesmeier.2003.413">Tiesmeier et al 2003</a>, <a class="bk_pop" href="#cebpa-aml.REF.shih.2006.604">Shih et al 2006</a>, <a class="bk_pop" href="#cebpa-aml.REF.hollink.2011.384">Hollink et al 2011</a>].</p></div><div id="cebpa-aml.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>To date, the majority of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> pathogenic variants are frameshift variants located in the N-terminal of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (preceding the internal start codon). Individuals commonly present with AML (of FAB subtypes M1, M2 or M4) following the acquisition of somatic <i>CEBPA</i> (and additional) pathogenic variants.</p></div><div id="cebpa-aml.Penetrance"><h3>Penetrance</h3><p>Analysis of pedigrees reported to date suggests that <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> pathogenic variants exhibit high <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for the development of AML [<a class="bk_pop" href="#cebpa-aml.REF.nickels.2013.254">Nickels et al 2013</a>, <a class="bk_pop" href="#cebpa-aml.REF.tawana.2015.1214">Tawana et al 2015</a>]. The penetrance of pathogenic variants may vary within and between families; data from ten families with germline <i>CEBPA</i> pathogenic variants revealed that more than 80% of confirmed or presumed obligate adult heterozygotes have developed disease to date [<a class="bk_pop" href="#cebpa-aml.REF.tawana.2015.1214">Tawana et al 2015</a>].</p></div><div id="cebpa-aml.Prevalence"><h3>Prevalence</h3><p><i>CEBPA-</i>associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML is very rare, with only eleven pedigrees reported as of this writing [<a class="bk_pop" href="#cebpa-aml.REF.smith.2004.2403">Smith et al 2004</a>, <a class="bk_pop" href="#cebpa-aml.REF.sellick.2005.1276">Sellick et al 2005</a>, <a class="bk_pop" href="#cebpa-aml.REF.pabst.2008.5088">Pabst et al 2008</a>, <a class="bk_pop" href="#cebpa-aml.REF.renneville.2009.804">Renneville et al 2009</a>, <a class="bk_pop" href="#cebpa-aml.REF.nanri.2010.237">Nanri et al 2010</a>, <a class="bk_pop" href="#cebpa-aml.REF.stelljes.2011.1209">Stelljes et al 2011</a>, <a class="bk_pop" href="#cebpa-aml.REF.taskesen.2011.2469">Taskesen et al 2011</a>, <a class="bk_pop" href="#cebpa-aml.REF.xiao.2011.5257">Xiao et al 2011</a>, <a class="bk_pop" href="#cebpa-aml.REF.debeljak.2013.e73">Debeljak et al 2013</a>, <a class="bk_pop" href="#cebpa-aml.REF.tawana.2015.1214">Tawana et al 2015</a>].</p><p>It has been suggested that 5%-10% of individuals with presumed <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> <i>CEBPA</i>-associated AML, may have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. <a class="bk_pop" href="#cebpa-aml.REF.pabst.2008.5088">Pabst et al [2008]</a> reported that two of 18 individuals (11%) with <i>CEBPA</i>-associated AML had a germline <i>CEBPA</i> pathogenic variant and a family history of AML. A larger series reported by <a class="bk_pop" href="#cebpa-aml.REF.taskesen.2011.2469">Taskesen et al [2011]</a> identified a germline <i>CEBPA</i> pathogenic variant in five of 71 individuals (7%); two of the five had a family history of AML.</p></div></div><div id="cebpa-aml.Genetically_Related_Allelic_Di"><h2 id="_cebpa-aml_Genetically_Related_Allelic_Di_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>CEBPA</i>.</p><p>Note: Sporadic <i>CEBPA-</i>associated acute myeloid leukemia (AML) is defined as AML in which a somatic <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is acquired in leukemic cells alone and not in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> (see <a href="#cebpa-aml.Molecular_Genetics">Molecular Genetics</a>). <i>CEBPA</i> has also been implicated in the solid tumors of individuals without AML [<a class="bk_pop" href="#cebpa-aml.REF.koschmieder.2009.619">Koschmieder et al 2009</a>].</p></div><div id="cebpa-aml.Differential_Diagnosis"><h2 id="_cebpa-aml_Differential_Diagnosis_">Differential Diagnosis</h2><p>The differential diagnosis for <i>CEBPA-</i>associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> acute myeloid leukemia (AML) includes:</p><ul><li class="half_rhythm"><div class="half_rhythm">Sporadic AML with somatic mutation of <i>CEBPA</i></div></li><li class="half_rhythm"><div class="half_rhythm">AML secondary to environmental exposures (e.g., benzene, radiation, chemotherapy)</div></li><li class="half_rhythm"><div class="half_rhythm">Sporadic AML with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member</div><div class="half_rhythm">Note: The more <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in a family (and the closer the relationships) the greater the likelihood of a common cause.</div></li></ul><p>Note: AML is a relatively rare disease (~13,300 cases/year in the US); therefore, pedigrees with more than one individual with AML could have a heritable predisposition or a common exposure [<a class="bk_pop" href="#cebpa-aml.REF.owen.2008.123">Owen et al 2008</a>].</p></div><div id="cebpa-aml.Management"><h2 id="_cebpa-aml_Management_">Management</h2><div id="cebpa-aml.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis of <i>CEBPA</i>-Associated Familial AML</h3><p>To establish the extent of disease and needs of an individual newly diagnosed with AML, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Cardiac scan in individuals with a personal history of &#x02013; or signs and symptoms suspicious for &#x02013; heart disease and in those who have received previous anthracycline therapy</div></li><li class="half_rhythm"><div>HLA typing in <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> of hematopoietic stem cell transplantation (HSCT)</div></li><li class="half_rhythm"><div>Lumbar puncture (LP) if symptoms suggest central nervous system disease. The timing of LP in AML is controversial.</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul><p>Evaluation of an individual with a confirmed diagnosis of <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML should include:</p><ul><li class="half_rhythm"><div>Assembly of a detailed <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> to identify additional <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and potential carriers of the inherited <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>;</div></li><li class="half_rhythm"><div>Recommendation of consultation with a genetic counselor for all at-risk family members;</div></li><li class="half_rhythm"><div>Molecular testing of family members at risk using buccal, salivary or skin DNA. Peripheral blood DNA may also be used in individuals with no history of preceding hematologic disease and normal complete blood count (CBC).</div><ul><li class="half_rhythm"><div>Comprehensive evaluation and screening of family members enables improved characterization of the clinical manifestations and <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> within the <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a>.</div></li><li class="half_rhythm"><div>Family members without the inherited <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may be offered human leukocyte antigen (HLA) typing to assess their compatibility for stem cell donation to their <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> relative.</div></li></ul></li></ul><p>Note: In all <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> leukemia syndromes with a known inherited <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, it is essential that screening of the pathogenic variant be performed in all relatives at risk prior to consideration of stem cell donation.</p></div><div id="cebpa-aml.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management of <i>CEBPA-</i>associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML does not differ from that of <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> <i>CEBPA-</i>associated AML [<a class="bk_pop" href="#cebpa-aml.REF12">National Comprehensive Cancer Network 2009</a>, <a class="bk_pop" href="#cebpa-aml.REF.d_hner.2010.453">D&#x000f6;hner et al 2010</a>].</p><p>Treatment usually includes cytarabine/anthracycline-based induction and cytarabine-based consolidation chemotherapy with or without HSCT according to clinical, <a class="def" href="/books/n/gene/glossary/def-item/cytogenetic/">cytogenetic</a>, and molecular risk. For younger individuals with AML (even those without a clear family history), there is now increasing awareness that <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> variants should be investigated and excluded prior to consideration of HSCT using sib/related donors. Specific treatment strategies are based on characteristics of the individual, response to chemotherapy, treatment setting, and protocol (if the individual is enrolled in a clinical trial). Note: Whenever possible, persons with AML should be treated as part of a clinical trial protocol.</p><p>Relapses are treated with cytarabine-based salvage chemotherapy followed by allogeneic HSCT (if a suitable donor is available and if cure is the intent of treatment).</p></div><div id="cebpa-aml.Prevention_of_Secondary_Compli"><h3>Prevention of Secondary Complications</h3><p>Prevention of secondary complications is similar to that for other types of AML:</p><ul><li class="half_rhythm"><div>Supportive care includes blood products such as red blood cell and platelet transfusions as needed and treatment of infections with antibiotics.</div></li><li class="half_rhythm"><div>Prophylactic antibiotics and antifungal agents are administered during periods of severe neutropenia including the consolidation and post-transplantation periods [<a class="bk_pop" href="#cebpa-aml.REF12">National Comprehensive Cancer Network 2009</a>].</div></li></ul></div><div id="cebpa-aml.Surveillance"><h3>Surveillance</h3><p><b>Affected individuals.</b> Surveillance for <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML is similar to that for other forms of AML. There are no generally accepted minimal residual disease (MRD) markers in <i>CEBPA-</i>associated AML or in most other AML subtypes with normal karyotypes.</p><p>Individuals are monitored and evaluated in accordance with administered treatment, clinical course, symptoms, and protocol, if enrolled in clinical trials. When complete remission is achieved and intensification therapy is complete, individuals are monitored with:</p><ul><li class="half_rhythm"><div>CBC and platelet counts every one to three months for two years with the frequency decreasing to every three to six months for up to five years;</div></li><li class="half_rhythm"><div>Bone marrow aspiration when cytopenia and/or an abnormal peripheral blood smear are present.</div></li></ul><p>Note: The use of flow cytometry for MRD monitoring is controversial.</p><p>Individuals with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who are cured of their initial disease episode may be at risk for new leukemic episodes, often occurring after a prolonged period of remission (&#x0003e;3 years post presentation) [<a class="bk_pop" href="#cebpa-aml.REF.pabst.2009.1343">Pabst et al 2009</a>, <a class="bk_pop" href="#cebpa-aml.REF.tawana.2015.1214">Tawana et al 2015</a>]. In light of these data, lifelong clinical surveillance is warranted to ensure prompt recognition and appropriate management of disease recurrence. Repeat testing of <i>CEBPA</i> at recurrence is important to help distinguish conventional relapse from new, independent leukemic episodes.</p><p><b>Asymptomatic carriers.</b> Asymptomatic individuals with a pathogenic <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a> may be reviewed with CBC profiling every six to 12 months. Bone marrow examination may be performed if there is an appropriate clinical indication (e.g., abnormalities in CBC). Referral for post-testing <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> should be considered as appropriate.</p></div><div id="cebpa-aml.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Use of sib or related donors for HSCT without prior assessment of the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a> in these individuals.</p></div><div id="cebpa-aml.Evaluation_of_Relatives_at_Ris"><h3>Evaluation of Relatives at Risk</h3><p>To date, all individuals with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic <i>CEBPA</i> variants have presented with overt AML without any preceding blood count abnormalities or myelodysplasia, this in contrast with other <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> leukemia syndromes such as those associated with germline <i>RUNX1</i> or <i>GATA2</i> pathogenic variants [<a class="bk_pop" href="#cebpa-aml.REF.nickels.2013.254">Nickels et al 2013</a>].</p><p>The decision to test for an inherited <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is ultimately governed by personal choice, the reassurance of regular clinical follow up, and provision of <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>. It is noteworthy that clinical monitoring may enable earlier diagnosis (and treatment) of AML, hence minimizing the risks associated with delayed presentation (e.g., severe anemia, neutropenic sepsis, and severe hemorrhage), providing further rationale for molecular evaluation of at-risk relatives. There are currently no preemptive treatments available for asymptomatic carriers of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> pathogenic variant.</p><p>See <a href="#cebpa-aml.Related_Genetic_Counseling_Iss">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="cebpa-aml.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Trials.gov</a> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="cebpa-aml.Genetic_Counseling"><h2 id="_cebpa-aml_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="cebpa-aml.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Predisposition to <i>CEBPA-</i>associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> acute myeloid leukemia (AML) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="cebpa-aml.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML have had an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent who shares the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>In rare cases, a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of apparently asymptomatic parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include a complete blood count (CBC) with hematologic indices, peripheral blood smear, and testing for the germline <i>CEBPA</i> pathogenic variant identified in the proband.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with <i>CEBPA-</i>associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML may appear to be negative because of early death of a parent before the onset of AML or late onset of AML in a parent. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</div></li><li class="half_rhythm"><div>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred s/he could potentially have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%.</div></li><li class="half_rhythm"><div>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents are still at increased risk for <i>CEBPA-</i>associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML as the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may demonstrate differences in disease manifestation and latency across family members.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk of other family members inheriting the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or has the germline pathogenic variant, his or her family members may be at risk.</p></div><div id="cebpa-aml.Related_Genetic_Counseling_Iss"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#cebpa-aml.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> If neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML has the pathogenic variant or clinical evidence of AML, the <i>CEBPA</i> pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Testing of at-risk asymptomatic family members.</b> If a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in a family member with AML, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> may be offered to at-risk family members in order to determine the need for clinical surveillance (see <a href="#cebpa-aml.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</a>).</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk in offspring of persons with known <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML is before pregnancy. Because <i>CEBPA</i>-associated familial AML is rare, general screening of individuals with AML or a family history of AML for a <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is not recommended for family planning purposes unless <i>CEBPA</i>-associated familial AML is suspected.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p>In AML generally, tissue banking that is performed for future research purposes should include banking of DNA, RNA, protein lysates, and cryopreserved cells.</p></div><div id="cebpa-aml.Prenatal_Testing_and_Preimplan"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for a pregnancy at increased risk for <i>CEBPA</i>-associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML are possible options.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="cebpa-aml.Resources"><h2 id="_cebpa-aml_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition/familial-acute-myeloid-leukemia-with-mutated-cebpa" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Familial acute myeloid leukemia with mutated CEBPA</a></div></li></ul></div><div id="cebpa-aml.Molecular_Genetics"><h2 id="_cebpa-aml_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="cebpa-aml.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>CEBPA-Associated Familial Acute Myeloid Leukemia (AML): Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47457/table/cebpa-aml.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cebpa-aml.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_cebpa-aml.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_cebpa-aml.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_cebpa-aml.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_cebpa-aml.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_cebpa-aml.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_cebpa-aml.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1050" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CEBPA</i></a></td><td headers="hd_b_cebpa-aml.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1050" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19q13<wbr style="display:inline-block"></wbr>​.11</a></td><td headers="hd_b_cebpa-aml.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P49715" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCAAT/enhancer-binding protein alpha</a></td><td headers="hd_b_cebpa-aml.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CEBPA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CEBPA</a></td><td headers="hd_b_cebpa-aml.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CEBPA[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CEBPA</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="cebpa-aml.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="cebpa-aml.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for CEBPA-Associated Familial Acute Myeloid Leukemia (AML) (<a href="/omim/116897,601626" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47457/table/cebpa-aml.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cebpa-aml.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/116897" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">116897</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CCAAT/ENHANCER-BINDING PROTEIN, ALPHA; CEBPA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601626" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601626</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LEUKEMIA, ACUTE MYELOID; AML</td></tr></tbody></table></div></div><div id="cebpa-aml.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p><i>CEBPA</i> encodes the CCAAT/enhancer-binding protein alpha (C/EBP&#x003b1;), a <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> that plays a key role in granulocyte development. A detailed review of the role of C/EBP&#x003b1; in human cancer has been published [<a class="bk_pop" href="#cebpa-aml.REF.koschmieder.2009.619">Koschmieder et al 2009</a>]. The role of mutation of <i>CEBPA</i> in the formation of acute myeloid leukemia (AML) is not well understood and is subject to ongoing research with several established mouse models simulating <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> N- terminal frameshift mutations [<a class="bk_pop" href="#cebpa-aml.REF.kirstetter.2008.299">Kirstetter et al 2008</a>], combined N- and C- terminal mutations [<a class="bk_pop" href="#cebpa-aml.REF.bereshchenko.2009.390">Bereshchenko et al 2009</a>], or conditional loss of C/EBP&#x003b1; [<a class="bk_pop" href="#cebpa-aml.REF.ye.2013.385">Ye et al 2013</a>].</p><p>Note: The terms <i>CEBPA</i>dm and <i>CEBPA</i>sm are used in the literature and refer to leukemic cells with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in both ("double mutation") or in a single copy of <i>CEBPA</i> ("single mutation"), respectively. These terms do not indicate the location of variants within the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or whether they are <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> or somatic. As mentioned previously, the latter distinction is based upon the identification of pathogenic variants in non-leukemic DNA. In individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> AML (caused by the somatic acquisition of <i>CEBPA</i> pathogenic variants), double and single mutated subtypes occur with approximately equal frequency. Notably, only double <i>CEBPA</i> mutations (predominantly combining N-terminal frameshift and C-terminal <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> insertions or deletions) are associated with favorable prognostic significance [<a class="bk_pop" href="#cebpa-aml.REF.dufour.2010.570">Dufour et al 2010</a>, <a class="bk_pop" href="#cebpa-aml.REF.green.2010.2739">Green et al 2010</a>].</p><p><b>Gene structure.</b>
<i>CEBPA</i> is a single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>; the primary <i>CEBPA</i> transcript (<a href="/nuccore/NM_004364.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004364.4</a>) is 2631 bp. Initiation of translation at two <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> AUG start codons (nucleotides 151-153 and 508-51) results in two C/EBP&#x003b1; protein <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>. For a detailed summary of gene and protein information, see <a href="/books/NBK47457/#cebpa-aml.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> variants.</b> A few benign variants in the <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> have been reported (see <a class="figpopup" href="/books/NBK47457/table/cebpa-aml.T.selected_cebpa_germline_vari/?report=objectonly" target="object" rid-figpopup="figcebpaamlTselectedcebpagermlinevari" rid-ob="figobcebpaamlTselectedcebpagermlinevari">Table 2</a>).</p><p><b>Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> variants.</b> All reported pathogenic germline variants are small deletions, duplications, or insertions resulting in a frameshift causing premature truncation at the N-terminal region of the C/EBP&#x003b1; protein. The analytic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> is expected to be &#x0003e;99% for variants within the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>. The germline variants identified to date are listed in <a class="figpopup" href="/books/NBK47457/table/cebpa-aml.T.selected_cebpa_germline_vari/?report=objectonly" target="object" rid-figpopup="figcebpaamlTselectedcebpagermlinevari" rid-ob="figobcebpaamlTselectedcebpagermlinevari">Table 2</a>; the c.217_218insC variant has been reported in two pedigrees. Thus far, reported germline variants have been small insertions/deletions that result in frameshifts in <i>CEBPA</i> regions that encode the N-terminal region of the protein and predict premature termination of synthesis of the full-length C/EBP&#x003b1; protein (see <b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>).</p><div id="cebpa-aml.T.selected_cebpa_germline_vari" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>CEBPA</i> Germline Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47457/table/cebpa-aml.T.selected_cebpa_germline_vari/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cebpa-aml.T.selected_cebpa_germline_vari_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.754G&#x0003e;T</td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala252Ser</td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_4" rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_004364.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004364<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_004355.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004355<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.713C&#x0003e;A</td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala238Glu</td></tr><tr><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.690G&#x0003e;T</td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr230=&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.68delC</td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro23ArgfsTer137</td></tr><tr><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.68dupC</td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His24AlafsTer84</td></tr><tr><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.141delC</td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala48ProfsTer112</td></tr><tr><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.198_201dupCTAC</td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile68LeufsTer41</td></tr><tr><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.318_319dupT</td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp107ValfsTer54</td></tr><tr><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.217_218insC&#x000a0;<sup>3</sup><br />(217insC)</td><td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_vari_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe73SerfsTer35</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="cebpa-aml.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="cebpa-aml.TF.2.2"><p class="no_margin">Indicates that no effect on protein level is expected</p></div></dd><dt>3. </dt><dd><div id="cebpa-aml.TF.2.3"><p class="no_margin">Reported in two pedigrees</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The use of alternative <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> non-AUG (GUG) and AUG start codons results in protein <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> with different lengths (see <a href="/books/NBK47457/#cebpa-aml.molgen.TA">Table A</a>, <b>Gene</b>). When translation initiates from the AUG at nucleotides 151-153, isoform a (also known as C/EBP-42) is produced; it is a 42-kd <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> of 358 amino acids <a href="/protein/NP_004355.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004355.2</a>. The full-length 42-kd protein contains two distinct N-terminal transactivation domains (mediate contact with transcriptional apparatus), a C-terminal basic region (DNA-binding), and a leucine zipper for dimerization.</p><p>Alternatively, when translation initiates from the alternative start site at AUG at nucleotides 508-510, a 30-kd (also known as C/EBP-30) isoform b of 239 amino acids that lacks the first transactivation <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and impairs interaction with the transcriptional apparatus (<a href="/protein/NP_001272758.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001272758.1</a>) is produced. The C-terminal domains are intact [<a class="bk_pop" href="#cebpa-aml.REF.pabst.2007.6829">Pabst &#x00026; Mueller 2007</a>, <a class="bk_pop" href="#cebpa-aml.REF.pabst.2009.5303">Pabst &#x00026; Mueller 2009</a>]. Evidence from cell culture identified C/EBP&#x003b1; protein as a tumor suppressor and an inhibitor of cell proliferation. Evidence from mouse models is consistent with the tumor suppressor activity being in the 42-kd isoform and transformation in the absence of 42 kd is mediated by a 30-kd isoform which has a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect leading to the formation of progenitors prone to deregulated proliferation and transformation [abstracted from <a class="bk_pop" href="#cebpa-aml.REF.pabst.2009.5303">Pabst &#x00026; Mueller 2009</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The reported <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>CEBPA</i> (<a class="figpopup" href="/books/NBK47457/table/cebpa-aml.T.selected_cebpa_germline_vari/?report=objectonly" target="object" rid-figpopup="figcebpaamlTselectedcebpagermlinevari" rid-ob="figobcebpaamlTselectedcebpagermlinevari">Table 2</a>) occur before codon 120 and cause/predict premature termination of synthesis of the full-length C/EBP&#x003b1; protein, with preservation of the 30-kd isoform. The 30-kd protein is believed to inhibit the action of the normal 42-kd protein encoded by the remaining normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> manner.</p><p><b>Somatic <i>CEBPA</i> pathogenic variants</b></p><ul><li class="half_rhythm"><div><b>In <i>CEBPA-</i>associated <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> AML.</b> The leukemic cells of most individuals with <i>CEBPA-</i>associated familial AML are <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>. In addition to the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> described above in the N-terminal region (see <b>Pathogenic germline variants</b>), the leukemic cells commonly acquire somatic C-terminal <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> pathogenic variant(s). Such variants disrupt the basic region and leucine zipper, impairing DNA binding as well as homo- and heterodimerization with other CEBP proteins and/or DNA binding [<a class="bk_pop" href="#cebpa-aml.REF.pabst.2007.6829">Pabst &#x00026; Mueller 2007</a>, <a class="bk_pop" href="#cebpa-aml.REF.pabst.2009.5303">Pabst &#x00026; Mueller 2009</a>].</div></li><li class="half_rhythm"><div><b>In <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> <i>CEBPA-</i>associated AML.</b> This is defined as AML in which a somatic <i>CEBPA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) is acquired in leukemic cells alone and not in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>. In 45%-55% of all persons with sporadic <i>CEBPA</i>-associated AML<i>,</i> two pathogenic <i>CEBPA</i> variants are detected (<i>CEBPA</i>dm); most frequently, a frameshift N-terminal variant is combined with a C-terminal <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> or <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> [<a class="bk_pop" href="#cebpa-aml.REF.green.2010.2739">Green et al 2010</a>, <a class="bk_pop" href="#cebpa-aml.REF.fasan.2014.794">Fasan et al 2014</a>].</div></li></ul></div></div><div id="cebpa-aml.References"><h2 id="_cebpa-aml_References_">References</h2><div id="cebpa-aml.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.arber.2008">Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Bloomfield CD. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4 ed. Lyon, France: WHO Press; 2008:110-23.</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.bereshchenko.2009.390">Bereshchenko O, Mancini E, Moore S, Bilbao D, M&#x000e5;nsson R, Luc S, Grover A, Jacobsen SE, Bryder D, Nerlov C. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. <span><span class="ref-journal">Cancer Cell. </span>2009;<span class="ref-vol">16</span>:390–400.</span> [<a href="/pubmed/19878871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19878871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.debeljak.2013.e73">Debeljak M, Kitanovski L, Paji&#x0010d; T, Jazbec J. Concordant acute myeloblastic leukemia in monozygotic twins with germline and shared somatic mutations in the gene for CCAAT-enhancer-binding protein &#x003b1; with 13 years difference at onset. <span><span class="ref-journal">Haematologica. </span>2013;<span class="ref-vol">98</span>:e73–4.</span> [<a href="/pmc/articles/PMC3696596/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3696596</span></a>] [<a href="/pubmed/23716546" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23716546</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.d_hner.2010.453">D&#x000f6;hner H, Estey EH, Amadori S, Appelbaum FR, B&#x000fc;chner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, L&#x000f6;wenberg B, Bloomfield CD. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">115</span>:453–74.</span> [<a href="/pubmed/19880497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19880497</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.dufour.2010.570">Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, B&#x000fc;chner T, W&#x000f6;rmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. <span><span class="ref-journal">J Clin Oncol. </span>2010;<span class="ref-vol">28</span>:570–7.</span> [<a href="/pubmed/20038735" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20038735</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.fasan.2014.794">Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S. The role of different genetic subtypes of CEBPA mutated AML. <span><span class="ref-journal">Leukemia. </span>2014;<span class="ref-vol">28</span>:794–803.</span> [<a href="/pubmed/24056881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24056881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.green.2010.2739">Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic Significance of CEBPA Mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. <span><span class="ref-journal">J Clin Oncol. </span>2010;<span class="ref-vol">28</span>:2739–47.</span> [<a href="/pubmed/20439648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20439648</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.hollink.2011.384">Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Zimmermann M, Peeters JK, Valk PJ, Balgobind BV, Sonneveld E, Kaspers GJ, de Bont ES, Trka J, Baruchel A, Creutzig U, Pieters R, Reinhardt D, Zwaan CM. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. <span><span class="ref-journal">Haematologica. </span>2011;<span class="ref-vol">96</span>:384–92.</span> [<a href="/pmc/articles/PMC3046269/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3046269</span></a>] [<a href="/pubmed/21134981" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21134981</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.kirstetter.2008.299">Kirstetter P, Schuster MB, Bereshchenko O, Moore S, Dvinge H, Kurz E, Theilgaard-M&#x000f6;nch K, M&#x000e5;nsson R, Pedersen TA, Pabst T, Schrock E, Porse BT, Jacobsen SE, Bertone P, Tenen DG, Nerlov C. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. <span><span class="ref-journal">Cancer Cell. </span>2008;<span class="ref-vol">13</span>:299–310.</span> [<a href="/pubmed/18394553" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18394553</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.koschmieder.2009.619">Koschmieder S, Balazs H, Levantini E, Tenen DG. Dysregulation of the C/EBP&#x003b1; differentiation pathway in human cancer. <span><span class="ref-journal">J Clin Oncol. </span>2009;<span class="ref-vol">27</span>:619–28.</span> [<a href="/pmc/articles/PMC2645860/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2645860</span></a>] [<a href="/pubmed/19075268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19075268</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.nanri.2010.237">Nanri T, Uike N, Kawakita T, Iwanaga E, Hoshino K, Mitsuya H, Asou N. A family harboring a germ-line N-terminal C/EBP&#x003b1; mutation and development of acute myeloblastic leukemia with an additional somatic C-terminal C/EBP&#x003b1; mutation. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2010;<span class="ref-vol">49</span>:237–41.</span> [<a href="/pubmed/19953636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19953636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF12">National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology&#x02122;. Available <a href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2009. Accessed 4-26-13.</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.nickels.2013.254">Nickels EM, Soodalter J, Churpek JE, Godley LA. Recognizing familial myeloid leukemia in adults. <span><span class="ref-journal">Ther Adv Hematol. </span>2013;<span class="ref-vol">4</span>:254–69.</span> [<a href="/pmc/articles/PMC3734901/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3734901</span></a>] [<a href="/pubmed/23926458" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23926458</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.owen.2008.123">Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukemia--a review. <span><span class="ref-journal">Br J Haematol. </span>2008;<span class="ref-vol">140</span>:123–32.</span> [<a href="/pubmed/18173751" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18173751</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.pabst.2009.1343">Pabst T, Eyholzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. <span><span class="ref-journal">Br J Cancer. </span>2009;<span class="ref-vol">100</span>:1343–46.</span> [<a href="/pmc/articles/PMC2676545/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2676545</span></a>] [<a href="/pubmed/19277035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19277035</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.pabst.2008.5088">Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. <span><span class="ref-journal">J Clin Oncol. </span>2008;<span class="ref-vol">26</span>:5088–93.</span> [<a href="/pubmed/18768433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18768433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.pabst.2007.6829">Pabst T, Mueller BU. Transcriptional dysregulation during myeloid transformation in AML. <span><span class="ref-journal">Oncogene. </span>2007;<span class="ref-vol">26</span>:6829–37.</span> [<a href="/pubmed/17934489" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17934489</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.pabst.2009.5303">Pabst T, Mueller BU. Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia. <span><span class="ref-journal">Clin Cancer Res. </span>2009;<span class="ref-vol">15</span>:5303–7.</span> [<a href="/pubmed/19706798" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19706798</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.renneville.2009.804">Renneville A, Mialou V, Philippe N, Kagialis-Girard S, Biggio V, Zabot MT, Thomas X, Bertrand Y, Preudhomme C. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. <span><span class="ref-journal">Leukemia. </span>2009;<span class="ref-vol">23</span>:804–6.</span> [<a href="/pubmed/18946494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18946494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.renneville.2008.915">Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, Preudhomme C. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. <span><span class="ref-journal">Leukemia. </span>2008;<span class="ref-vol">22</span>:915–31.</span> [<a href="/pubmed/18288131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18288131</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.sellick.2005.1276">Sellick GS, Spendlove HE, Catovsky D, Pritchard-Jones K, Houlston RS. Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukemia. <span><span class="ref-journal">Leukemia. </span>2005;<span class="ref-vol">19</span>:1276–8.</span> [<a href="/pubmed/15902292" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15902292</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.shih.2006.604">Shih LY, Liang DC, Huang CF, Wu JH, Lin TL, Wang PN, Dunn P, Kuo MC, Tang TC. AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples. <span><span class="ref-journal">Leukemia. </span>2006;<span class="ref-vol">20</span>:604–9.</span> [<a href="/pubmed/16453003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16453003</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.smith.2004.2403">Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">351</span>:2403–7.</span> [<a href="/pubmed/15575056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15575056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.stelljes.2011.1209">Stelljes M, Corbacioglu A, Schlenk RF, D&#x000f6;hner K, Fr&#x000fc;hwald MC, Rossig C, Ehlert K, Silling G, M&#x000fc;ller-Tidow C, Juergens H, D&#x000f6;hner H, Berdel WE, Kienast J, Koschmieder S. Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein &#x003b1; from hematopoietic cells in a family with AML. <span><span class="ref-journal">Leukemia. </span>2011;<span class="ref-vol">25</span>:1209–10.</span> [<a href="/pubmed/21455213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21455213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.taskesen.2011.2469">Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ, van der Poel-van de Luytgaarde SC, Damm F, Krauter J, Ganser A, Schlenk RF, L&#x000f6;wenberg B, Delwel R, D&#x000f6;hner H, Valk PJ, D&#x000f6;hner K. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:2469–75.</span> [<a href="/pubmed/21177436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21177436</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.tawana.2015.1214">Tawana K, Wang J, Renneville A, B&#x000f6;d&#x000f6;r C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, D&#x000f6;hner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J. Disease evolution and outcomes in familial AML with germline CEBPA mutations. <span><span class="ref-journal">Blood. </span>2015;<span class="ref-vol">126</span>:1214–23.</span> [<a href="/pubmed/26162409" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26162409</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.tiesmeier.2003.413">Tiesmeier J, Czwalinna A, M&#x000fc;ller-Tidow C, Krauter J, Serve H, Heil G, Ganser A, Verbeek W. Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia. <span><span class="ref-journal">Br J Haematol. </span>2003;<span class="ref-vol">123</span>:413–9.</span> [<a href="/pubmed/14616999" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14616999</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.xiao.2011.5257">Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W, Zhang L, Wang Y, Liu L, Wu K, Yu X, Cai Z, Lin M, Ye X, Huang H. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:5257–60.</span> [<a href="/pubmed/21403128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21403128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cebpa-aml.REF.ye.2013.385">Ye M, Zhang H, Amabile G, Yang H, Staber PB, Zhang P, Levantini E, Alberich-Jord&#x000e0; M, Zhang J, Kawasaki A, Tenen DG. C/EBPa controls acquisition and maintenance of adult haematopoietic stem cell quiescence. <span><span class="ref-journal">Nat Cell Biol. </span>2013;<span class="ref-vol">15</span>:385–94.</span> [<a href="/pmc/articles/PMC3781213/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3781213</span></a>] [<a href="/pubmed/23502316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23502316</span></a>]</div></li></ul></div></div><div id="cebpa-aml.Chapter_Notes"><h2 id="_cebpa-aml_Chapter_Notes_">Chapter Notes</h2><div id="cebpa-aml.Author_History"><h3>Author History</h3><p>Jude Fitzgibbon, PhD (2016-present)<br />Roger D Klein, MD, JD; Cleveland Clinic (2010-2016)<br />Guido Marcucci, MD; Ohio State University (2010-2016)<br />Kiran Tawana, MBChB, FRCPath (2016-present)</p></div><div id="cebpa-aml.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>28 April 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 October 2010 (me) Review posted live</div></li><li class="half_rhythm"><div>30 December 2009 (rdk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK47457</span><span class="label">PMID: <a href="/pubmed/20963938" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20963938</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cdk13-dis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/charge/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK47457&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK47457/?report=reader">PubReader</a></li><li><a href="/books/NBK47457/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK47457" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK47457" style="display:none" title="Cite this Page"><div class="bk_tt">Tawana K, Fitzgibbon J. CEBPA-Associated Familial Acute Myeloid Leukemia (AML) 2010 Oct 21 [Updated 2016 Apr 28]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK47457/pdf/Bookshelf_NBK47457.pdf">PDF version of this page</a> (445K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#cebpa-aml.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#cebpa-aml.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#cebpa-aml.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#cebpa-aml.Genetically_Related_Allelic_Di" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#cebpa-aml.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#cebpa-aml.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#cebpa-aml.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#cebpa-aml.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#cebpa-aml.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#cebpa-aml.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#cebpa-aml.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1788[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">DNMT3A</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4291[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MLF1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=26511[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CHIC2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4869[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NPM1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3845[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KRAS</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1050[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CEBPA</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8021[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NUP214</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=865[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CBFB</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2322[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FLT3</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8301[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PICALM</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8028[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MLLT10</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6455[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SH3GL1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=64324[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NSD1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2624[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GATA2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7015[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TERT</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2120[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ETV6</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3717[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">JAK2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=861[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RUNX1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3815[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KIT</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4026[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">LPP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK47457+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=2346896" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=2346896" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=2346896" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=2346896" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28637622" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Familial CEBPA-mutated acute myeloid leukemia.</a><span class="source">[Semin Hematol. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Familial CEBPA-mutated acute myeloid leukemia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tawana K, Rio-Machin A, Preudhomme C, Fitzgibbon J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Semin Hematol. 2017 Apr; 54(2):87-93. Epub 2017 Apr 7.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301287" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Autoimmune Lymphoproliferative Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Autoimmune Lymphoproliferative Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bleesing JJH, Nagaraj CB, Zhang K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301705" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ELANE</i>-Related Neutropenia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ELANE</i>-Related Neutropenia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dale DC, Makaryan V. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24761742" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">DICER1</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">DICER1</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Doros L, Schultz KA, Stewart DR, Bauer AJ, Williams G, Rossi CT, Carr A, Yang J, Dehner LP, Messinger Y, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18768433" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.</a><span class="source">[J Clin Oncol. 2008]</span><div class="brieflinkpop offscreen_noflow">Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Oncol. 2008 Nov 1; 26(31):5088-93. Epub 2008 Sep 2.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20963938" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20963938" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0415c8dd21425a250fe4cf">CEBPA-Associated Familial Acute Myeloid Leukemia (AML) - GeneReviews®</a><div class="ralinkpop offscreen_noflow">CEBPA-Associated Familial Acute Myeloid Leukemia (AML) - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:07:04-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C0279E04060010000000006AB0243&amp;ncbi_session=CE8C0279E0415C71_1707SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK47457%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK47457&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK47457/&amp;ncbi_pagename=CEBPA-Associated Familial Acute Myeloid Leukemia (AML) - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C0279E0415C71_1707SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>